Abstract
Background & aims: Cirrhosis is associated with immune dysregulation and hyporesponsiveness to several vaccines including those against COVID-19. Our aim was to compare outcomes between patients with cirrhosis who received 3 doses of either the Pfizer BNT162b2 mRNA or Moderna mRNA-1273 vaccines to a propensity-matched control group of patients at similar risk of infection who received 2 doses.
Methods: This was a retrospective cohort study of patients with cirrhosis who received 2 or 3 doses of a COVID-19 mRNA vaccine at the Veterans Health Administration. Participants who received 3 doses of the vaccine (n = 13,041) were propensity score matched with 13,041 controls who received 2 doses, and studied between July 18, 2021 and February 11, 2022, when B.1.617.2 (delta) and B.1.1.529 (omicron) were the predominant variants. Outcomes were aggregated as all cases with COVID-19, symptomatic COVD-19, with at least moderate COVID-19, or severe or critical COVID-19.
Results: Receipt of the third dose of a COVID-19 mRNA vaccine was associated with an 80.7% reduction in COVID-19 (95% CI 39.2-89.1, p <0.001), an 80.4% reduction in symptomatic COVID-19, an 80% reduction in moderate, severe or critical COVID-19, (95% CI 34.5-87.6%, p = 0.005), a 100% reduction in severe or critical COVID-19 (95% CI 99.2-100.0, p = 0.01), and a 100% reduction in COVID-19-related death (95% CI 99.8-100.0, p = 0.007). The magnitude of reduction in COVID-19 was greater with the third dose of BNT 162b2 than mRNA-1273 and among participants with compensated rather than decompensated cirrhosis.
Conclusions: Administration of a third dose of a COVID-19 mRNA vaccine was associated with a more significant reduction in COVID-19 in patients with cirrhosis than in the general population, suggesting that the third dose can overcome vaccine hyporesponsiveness in this population.
Lay summary: Cirrhosis is associated with decreased responsiveness to several vaccines, including those against COVID-19. In this study of 26,082 participants with cirrhosis during the delta and omicron surge, receipt of the third dose of the vaccine was associated with an 80% reduction in COVID-19, a 100% reduction in severe/critical COVID-19, and a 100% reduction in COVID-19-related death. These findings support the importance of a third dose of mRNA vaccine among patients with cirrhosis.
Keywords: BNT162b2 mRNA; COVID-19 vaccines; booster dose; chronic liver disease; hepatic decompensation; mRNA-1273.
【저자키워드】 COVID-19 vaccines, booster dose, mRNA-1273., BNT162b2 mRNA, chronic liver disease, hepatic decompensation, 【초록키워드】 COVID-19, Vaccine, Vaccines, mRNA vaccine, mRNA-1273, B.1.617.2, outcome, variants, Moderate COVID-19, BNT162b2, Pfizer, symptomatic, cirrhosis, Patient, Control, B.1.1.529, General population, Critical, liver, moderate, booster, dose, COVD-19, risk of infection, immune dysregulation, Support, retrospective cohort study, control group, 95% CI, participant, receipt, COVID-19-related death, doses, Moderna mRNA-1273 vaccine, veteran, hyporesponsiveness, greater, overcome, magnitude, the vaccine, predominant, reduction in, BNT, compensated, COVID-19 in patient, with COVID-19, 【제목키워드】 COVID-19, Vaccine, mRNA vaccine, cirrhosis, Patient, dose, hyporesponsiveness, appear, overcome,